Reata has four Phase 2 programs expected to produce data by mid-2009

Overview

Reata also has a robust pipeline of drug candidates and discovery programs built around two proprietary technology platforms – the AIMs and our protein folding chaperone technology. Currently, Reata is pursuing four Phase 2 development programs with its two lead molecules.

	Pre-Clinical	Phase I	Phase II	Phase III
RTA 402 Cancer (Oral Once Daily AIM)   Pancreatic Cancer Solid Tumors
RTA 402 Renal/CV (Oral Once Daily AIM) Chronic Renal Dysfunction
RTA 402 Autoimmune (Oral Once Daily AIM) Rheumatoid Arthritis
Berubicin RTA 744 (Anthracycline crossing blood-brain barrier) Brain Metastases from Breast Cancer   Glioblastoma Multiforme (GBM)
RTA 404 Autoimmune (Oral Once Daily AIM) Multiple Sclerosis
RTA 801 (SODA1 Protein Folding Stabilizer) Amyotrophic Lateral Sclerosis (ALS)